Shots:
- Y-Biologics to receive ~$2M up front and eligible to receive ~$85M as development, regulatory, & commercialization milestones along with royalties on sales in the territory
- 3D Medicines will get an exclusive right to develop, manufacture, and commercialize YBL-013 in China with the expansion of collaboration in the US and other regions
- Both the companies will share IND development costs. YBL-013 is a T cell bi-specific engager based on ALiCE platform technology and targets CD3 on T cell and PD-L1 on cancer cell
Click here to read full press release/ article | Ref: PRNasia | Image: Y-Biologics
The post Y-Biologics Signs a License Agreement with 3D Medicines for YBL-013 in the Territory of Greater China first appeared on PharmaShots.
